Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 3/20 | 0.42 |
| ▸ | ROCK2 | O75116 | 7/20 | 0.41 |
| ▸ | GCK | P35557 | 2/20 | 0.40 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
| ▸ | PIK3CG | P48736 | 4/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.39 |
| ▸ | NPC1 | O15118 | 1/20 | 0.39 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.39 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.39 |
| ▸ | HPGD | P15428 | 1/20 | 0.39 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.39 |
| ▸ | RAB9A | P51151 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
| ▸ | POLB | P06746 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL799348 | 0.93 | ROCK2 (0.39) | LMNAROCK2GCKMEN1KMT2A | |
| SCHEMBL798950 | 0.93 | ROCK2 (0.39) | LMNAROCK2GCKMEN1KMT2A | |
| SCHEMBL172152 | 0.89 | LMNA (0.43) | LMNAROCK2GCKMEN1KMT2A | |
| SCHEMBL799149 | 0.89 | LMNA (0.43) | LMNAROCK2GCKMEN1KMT2A | |
| SCHEMBL799155 | 0.85 | ROCK2 (0.39) | ROCK2GCKPIK3CGKDM4ENPC1 | |
| SCHEMBL799096 | 0.84 | ROCK2 (0.48) | LMNAROCK2MEN1KMT2APIK3CG | |
| SCHEMBL799148 | 0.83 | LMNA (0.43) | LMNAROCK2GCKMEN1KMT2A | |
| SCHEMBL805072 | 0.83 | LMNA (0.44) | LMNAGCKMEN1KMT2APIK3CG | |
| SCHEMBL799272 | 0.83 | PIK3CG (0.51) | LMNAROCK2GCKPIK3CGKDM4E | |
| SCHEMBL799051 | 0.82 | PIK3CG (0.47) | LMNAROCK2GCKMEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120071475-A1 | UREA DERIVATIVES HAVING PI3K-INHIBITING ACTIVITY | SHIONOGI & CO., LTD. (JP) | 2012-03-22 | — | — | US | disclosed |
| US-20120071475-A1 | UREA DERIVATIVES HAVING PI3K-INHIBITING ACTIVITY | SHIONOGI & CO., LTD. (JP) | 2012-03-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120071475-A1 | UREA DERIVATIVES HAVING PI3K-INHIBITING ACTIVITY | MTOR, STAT3, SLC14A1 | LMNA 4258/4885ROCK2 2264/4885GCK 786/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.